Ezgi Ayse Cakir, Ayşegül Özyılmaz, Merve Alpay, Sare Uyurca
{"title":"Could serum IGF-1 and IGF-2 serve as potential biomarkers in idiopathic Parkinson’s disease? A correlation with disease stages","authors":"Ezgi Ayse Cakir, Ayşegül Özyılmaz, Merve Alpay, Sare Uyurca","doi":"10.1007/s13760-025-02839-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Idiopathic Parkinson’s Disease (IPD) is a progressive neurodegenerative disorder characterized by tremor, rigidity, akinesia, and postural instability. Dysfunction in lysosomal autophagy, involving proteins like IGF-1(insulin like growth factor) and IGF-2, contributes to neuroinflammation and neuronal death. Reliable biomarkers for IPD diagnosis and monitoring remain elusive. This study investigates serum IGF-1 and IGF-2 levels to evaluate their biomarker potential.</p><h3>Methods</h3><p>Eighty-four individuals (43 IPD patients, 41 controls) aged 18–79 were included. Diagnoses followed the UK Brain Bank Criteria; disease severity was assessed with Hoehn & Yahr (H&Y) and UPDRS scales. Serum IGF-1 and IGF-2 levels were measured using ELISA. Statistical analyses were performed using SPSS v30.0. Normality was assessed via the Shapiro-Wilk test. Based on data distribution, Independent Samples t-test, Mann-Whitney U, Chi-square, Kruskal-Wallis, Spearman correlation, and ROC analysis were applied. A p-value < 0.05 was considered statistically significant.</p><h3>Results</h3><p>Serum IGF-2 levels were significantly higher in patients compared to controls (<i>p</i> = 0.006), while IGF-1 levels showed no significant difference. Both IGF-1 and IGF-2 levels displayed negatively correlated with disease duration (<i>p</i> = 0.044 and <i>p</i> = 0.008). Although IGF-1 and IGF-2 levels appeared elevated at H&Y stage 2, the differences were not statistically significant. No significant associations were observed between IGF levels and UPDRS scores or medication use.</p><h3>Conclusion</h3><p>Elevated serum IGF-2 levels indicate its potential as a biomarker for IPD. These findings contribute to a better understanding of the role of IGF-1 and IGF-2 in IPD pathophysiology, suggesting that further multicenter studies are needed to clarify their diagnostic and therapeutic potential.</p></div>","PeriodicalId":7042,"journal":{"name":"Acta neurologica Belgica","volume":"125 4","pages":"1083 - 1090"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s13760-025-02839-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Idiopathic Parkinson’s Disease (IPD) is a progressive neurodegenerative disorder characterized by tremor, rigidity, akinesia, and postural instability. Dysfunction in lysosomal autophagy, involving proteins like IGF-1(insulin like growth factor) and IGF-2, contributes to neuroinflammation and neuronal death. Reliable biomarkers for IPD diagnosis and monitoring remain elusive. This study investigates serum IGF-1 and IGF-2 levels to evaluate their biomarker potential.
Methods
Eighty-four individuals (43 IPD patients, 41 controls) aged 18–79 were included. Diagnoses followed the UK Brain Bank Criteria; disease severity was assessed with Hoehn & Yahr (H&Y) and UPDRS scales. Serum IGF-1 and IGF-2 levels were measured using ELISA. Statistical analyses were performed using SPSS v30.0. Normality was assessed via the Shapiro-Wilk test. Based on data distribution, Independent Samples t-test, Mann-Whitney U, Chi-square, Kruskal-Wallis, Spearman correlation, and ROC analysis were applied. A p-value < 0.05 was considered statistically significant.
Results
Serum IGF-2 levels were significantly higher in patients compared to controls (p = 0.006), while IGF-1 levels showed no significant difference. Both IGF-1 and IGF-2 levels displayed negatively correlated with disease duration (p = 0.044 and p = 0.008). Although IGF-1 and IGF-2 levels appeared elevated at H&Y stage 2, the differences were not statistically significant. No significant associations were observed between IGF levels and UPDRS scores or medication use.
Conclusion
Elevated serum IGF-2 levels indicate its potential as a biomarker for IPD. These findings contribute to a better understanding of the role of IGF-1 and IGF-2 in IPD pathophysiology, suggesting that further multicenter studies are needed to clarify their diagnostic and therapeutic potential.
期刊介绍:
Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor.
Acta Neurologica Belgica is the official journal of the following national societies:
Belgian Neurological Society
Belgian Society for Neuroscience
Belgian Society of Clinical Neurophysiology
Belgian Pediatric Neurology Society
Belgian Study Group of Multiple Sclerosis
Belgian Stroke Council
Belgian Headache Society
Belgian Study Group of Neuropathology